<DOC>
	<DOCNO>NCT01480232</DOCNO>
	<brief_summary>This study design evaluate initial evidence efficacy investigational medicine , EVP-6124 , improve smoke cessation outcome without standard taper nicotine replacement therapy ( NRT ) healthy nicotine dependent smoker</brief_summary>
	<brief_title>A Safety Cognitive Function Study EVP-6124 Versus Placebo Subjects With Nicotine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Nicotinic Agonists</mesh_term>
	<criteria>Selfreport smoking average ≥10 cigarettes/day 6 month expire carbon monoxide ( CO ) ≥10 part per million ( ppm ) urine cotinine ≥ 100 ng/mL screen selfreport smoking average 59 cigarettes/day 6 month urine cotinine ≥30ng/ml screen Have negative urine drug screen screen Fertile , sexually active subject ( male female ) must use effective method contraception first dose study drug 3 month last dose study drug If female capable conception , must negative urine Human chorionic gonadotrophin ( hCG ) pregnancy test screen Day 1 Have unstable medical illness hospitalization treatment likely within 6 month Have lifethreatening arrhythmia , cerebrovascular cardiovascular event within 6 month enrollment Have liver function test elevate &gt; 2.5 time upper limit normal range Have tumor seizure disorder Currently use tobacco nicotinecontaining product unwilling try quit Have 6month history substance use disorder nicotine caffeine major depressive disorder Have history multiple adverse drug reaction Nonresponse ( past 3 month ) nicotine replacement therapy ( NRT ) &gt; 20 mg/day , bupropion &gt; 150 mg/day , varenicline 2 mg/day ≥4 week Use exclude concomitant medication Hospitalization reason within 30 day screen Use investigational drug device within 30 day screen Have clinically significant abnormal serum electrolyte Have insufficiently control diabetes mellitus Have renal insufficiency ( serum creatinine &gt; 1.8 mg/dL ) Malignant tumor within last 5 year , exception squamous basal cell carcinoma cervical carcinoma situ Have clinically significant cardiovascular abnormality screen EKG Lifetime history schizophrenia , bipolar disorder , posttraumatic stress disorder , bulimia , organic mental disorder , dementia , pervasive developmental disorder Have untreated , clinically significant hypothyroidism hyperthyroidism Have positive selfreport human immunodeficiency virus infection Females pregnant nursing Any experimental drug currently within 30 day baseline Have serious risk suicide Have screen electrocardiogram ( ECG ) correct QT ( QTc ) interval use Bazett 's formula &gt; 450 msec male &gt; 470 msec female presence clinically significant cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>